<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171584</url>
  </required_header>
  <id_info>
    <org_study_id>oncho</org_study_id>
    <nct_id>NCT03171584</nct_id>
  </id_info>
  <brief_title>Antifungal Drugs in Treatment of Onychomycosis</brief_title>
  <official_title>Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Onychomycosis refers to the fungal infection of the fingernails or toenails, caused by&#xD;
      dermatophytes, yeast and non-dermatophyte molds that lead to distortion, discoloration,&#xD;
      thickening and detachment from the nail bed&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Onychomycosis accounts for up to 30% of all superficial infections of skin and constitutes&#xD;
      about a half of all nail abnormalities; affecting approximately 5% of population worldwide&#xD;
&#xD;
      The prevalence of onychomycosis is determined by age, social class, occupation, climate,&#xD;
      living environment and frequency of travel Despite being common dermatological presentation,&#xD;
      the exact prevalence of onychomycosis remains largely unknown.&#xD;
&#xD;
      Toenails are more commonly affected than fingernails due to slower rate of growth of the&#xD;
      former, reduced blood supply and usual confinement in dark moist environments The infection&#xD;
      is more common in adult males (particularly elderly &gt; 60 yrs of age), diabetics,&#xD;
      immunocompromised individuals (e.g. HIV positive), individuals with peripheral vascular&#xD;
      (arterial) disease, previous tineapedis infection, history of trauma to the nail, or those&#xD;
      with a family history of onychomycosis Dermatophytes whether pathogenic or saprophytes are&#xD;
      the commonest causative nail invaders Dermatophytic onychomycosis can be divided into four&#xD;
      major clinical types on the basis of their presenting clinical features; distal and lateral&#xD;
      subungualonychomycosis (DLSO), proximal subungualonychomycosis (PSO), white superficial&#xD;
      onychomycosis (WSO) and total dystrophic onychomycosis (TDO) , Among these,distal and lateral&#xD;
      subungualonychomycosis( DLSO) is the most common form.&#xD;
&#xD;
      Clinical diagnosis by physical examination alone can be inaccurate as many non infectious&#xD;
      conditions that mimic onychomycosis like lichen planus, psoriasis need to be ruled out .&#xD;
      Various laboratory techniques have been used to accurately diagnose onychomycosis, with&#xD;
      microscopy by KOH and fungal culture being the most frequently used The histopathology of&#xD;
      nail clippings can be utilized for diagnosing onychomycosis, with periodic acid-Schiff (PAS)&#xD;
      stain that allows easy visualization of fungal hyphae . Digital dermoscopy, also called&#xD;
      onychoscopy, is an easy and quick procedure that allows differential diagnosis of&#xD;
      onychomycosis from the common nail dystrophies.&#xD;
&#xD;
      Dystrophic nails can be a social impediment causing significant embarrassment that affects&#xD;
      patient's self-esteem. In addition, thickened nails can be painful, interfere with the&#xD;
      function of the nail unit and may cause discomfort in walking, standing and exercising.&#xD;
&#xD;
      Though initially presenting as a cosmetic problem, it can eventually lead to permanent&#xD;
      disfigurement of the nails and serve as a source of other fungal infections . Due to these&#xD;
      significant effects specific questionnaire was designed and validated to assess quality of&#xD;
      life in patients with onychomycosis&#xD;
&#xD;
      Treatment is chosen depending on the modality of nail invasion, fungus species and the number&#xD;
      of affected nails. Oral treatments are often limited by drug interactions, while topical&#xD;
      antifungal lacquers have less efficacy . Surgery or nail debridement is another invasive&#xD;
      treatment option in limited resistant cases .&#xD;
&#xD;
      The use of griseofulvin and ketoconazole is problematic, as there are typically high relapse&#xD;
      rates of 50-85%. In addition, treatment must be continued for a long duration with risky&#xD;
      systemic side effects.&#xD;
&#xD;
      Fluconazole, itraconazole and terbinafine are relatively safe antifungal drugs that have been&#xD;
      widely used with improved treatment success, producing a mycological cure in more than 90% of&#xD;
      fingernail infections and in about 80% of toenail infections&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate of patients</measure>
    <time_frame>one year</time_frame>
    <description>Percentage of patients with complete cure in every group</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Antifungal Drugs in Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Terbinafine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm (1) will receive Terbinafine (250mg/day for 6 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine</intervention_name>
    <description>oral antifungal drugs</description>
    <arm_group_label>Fluconazole group</arm_group_label>
    <arm_group_label>Itraconazole group</arm_group_label>
    <arm_group_label>Terbinafine group</arm_group_label>
    <other_name>Fluconazole</other_name>
    <other_name>Itraconazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with finger nail onychomycosis of different sex and age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients taking immunosuppressive drugs or drugs affecting nail colour or growth.&#xD;
&#xD;
          2. Patients with previous trauma to the nails.&#xD;
&#xD;
          3. Pregnant and lactating women.&#xD;
&#xD;
          4. Patients with 20 nail dystrophy.&#xD;
&#xD;
          5. Patients with keratinization disorders as psoriasis and chronic medical or cutaneous&#xD;
             diseases.&#xD;
&#xD;
          6. Patients with chronic medical or cutaneous diseases that may affect quality of life.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emad Abd El-raheem Taha, MD</last_name>
    <phone>01006462294</phone>
    <email>emadtaha76@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radwa Mohamed Bakr</last_name>
    <phone>01119988115</phone>
    <email>radwabakr2011@hotmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>de SÃ¡ DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Feb;15(1):17-36. doi: 10.1007/s40257-013-0056-2. Review.</citation>
    <PMID>24352873</PMID>
  </results_reference>
  <results_reference>
    <citation>Grover C, Khurana A. Onychomycosis: newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol. 2012 May-Jun;78(3):263-70. doi: 10.4103/0378-6323.95440. Review.</citation>
    <PMID>22565425</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta AK, Ryder JE, Summerbell RC. Onychomycosis: classification and diagnosis. J Drugs Dermatol. 2004 Jan-Feb;3(1):51-6. Review.</citation>
    <PMID>14964746</PMID>
  </results_reference>
  <results_reference>
    <citation>Neupane S, Pokhrel DB, Pokhrel BM. Onychomycosis: a clinico-epidemiological study. Nepal Med Coll J. 2009 Jun;11(2):92-5.</citation>
    <PMID>19968146</PMID>
  </results_reference>
  <results_reference>
    <citation>Wulkan AJ, Tosti A. Pediatric nail conditions. Clin Dermatol. 2013 Sep-Oct;31(5):564-72. doi: 10.1016/j.clindermatol.2013.06.017. Review.</citation>
    <PMID>24079585</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>May 28, 2017</last_update_submitted>
  <last_update_submitted_qc>May 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>AMLadeed</investigator_full_name>
    <investigator_title>A comparative Study of Systemic antifungal drugs used in treatment of onychomycosis</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

